Biopharmaceutical company Apricus Biosciences, Inc. has announced that it has enrolled the first patient its phase 2a clinical trial for the assessment of the company’s main candidate for treating Raynaud’s phenomenon secondary to scleroderma. The investigational drug, which is comprised of an on-demand topical cream for the afflicted extremities, is…
The National Institutes of Health (NIH) recently granted two $450,000 Phase I Small Business Technology Transfer (STTR) grants to Cureveda LLC, who is currently developing new therapies for the treatment of inflammatory and fibrotic diseases, such as scleroderma. The company will invest the grants in its ongoing preclinical studies that are going to…
iBio, Inc. has released the latest information on the development of IBIO-CFB03, a therapy designed to address significant unmet medical needs for the treatment of fibrotic diseases, including systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF). The company, which creates plant-derived pharmaceutical products, presented the news to their shareholders and other attendees at…
Cytori Therapeutics, Inc., a company developing autologous ADRCs-based cell therapies for the treatment of several conditions, including scleroderma, has been granted conditional approval by the U.S. Food and Drug Administration (FDA), for an Investigational Device Exemption (IDE) for their investigational scleroderma therapy. The pivotal trial, dubbed “STAR,” aims to evaluate the potential of Cytori Cell Therapy,…
Biopharmaceutical company Apricus Biosciences, Inc. announced it has successfully enrolled the first patient for a Phase 2a clinical trial for RayVa™, the company’s frontline candidate for scleroderma-related Raynaud’s phenomenon. Scleroderma, classified among autoimmune rheumatic diseases, causes hardening or spontaneous scarring of the skin, internal organs,…
The Chief Executive Officer of emerging growth drug development company Corbus Pharmaceuticals Holdings, Inc. has been invited to present at the Virtual Investor Conferences, a live and interactive online event that will take place on Thursday, December 4 at 11:30 a.m. EST. Yuval Cohen, Ph.D., CEO of Corbus,…
The University of California San Francisco (UCSF) will be hosting a free, live webinar entitled “Emerging Therapies in Pulmonary Fibrosis: Their Relevance for Scleroderma Patients,” to be conducted by the university’s Director of Biological Research for the Interstitial Lung Disease Program, Dr. Paul Wolters. It will be broadcasted on the Scleroderma…
A woman recently engaged in a 48 – hour hunger strike to raise awareness and funds to help people suffering from scleroderma. Erika Pompa, a San Antonio, Texas resident and mother of two, decided to stay for two days on the sidewalk of a local restaurant, starving herself to support…
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application to RayVa, a product candidate being developed by Apricus Biosciences for the treatment of Raynaud’s phenomenon, including the treatment of the condition secondary to Scleroderma. The Notice of Allowance means that the USPTO is now…
Mike Berry had a life like any other 42-year-old man — married to wife Christine and a newborn son, Troy — when he was diagnosed with systemic scleroderma fourteen months ago. Berry, who was born in Kingston, Canada, started experiencing shortness of breath, and the physicians discovered that he suffered…
Get regular updates to your inbox.